Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: A phase 2 trial of the Minnie pearl cancer research network

Cancer

Volumn 113, Issue 4, 2008, Pages 765-771

  Hainsworth, John D ^a,b   Spigel, David R ^a,b   Barton, John ^a   Farley, Cindy ^b   Schreeder, Marshall ^c   Hon, Jeremy ^a   Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Clearview Cancer Institute   (United States)

Author keywords

Bortezomib; Multiple myeloma; Proteasome inhibitors; Response rate

Indexed keywords

BORTEZOMIB;

ADULT; AGED; ANAMNESIS; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; EPIGASTRIC PAIN; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOTENSION; LABORATORY TEST; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA AND VOMITING; NEUROLOGIC EXAMINATION; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; RECURRENT CANCER; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; SURVIVAL ANALYSIS;

EID: 50249154228     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23606     Document Type: Article

References (21)

1. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
2. Richardson P, Sonneveld P, Schuster M, et al. Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial [abstract]. Blood. 2005; 106:715a. Abstract 2547.
3. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007; 110:3557-3560.
4. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-2622.
5. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003;426:895-899.
6. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20: 4420-4427.
7. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
8. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2108-2121.
9. deVos S, Dakhil S, McLaughlin P, et al. Bortezomib plus rituximab in patients with indolent non-Hodgkin's lymphoma (NHL): a phase 2 study [abstract]. Blood. 2005;106: 10a. Abstract 17.
10. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473.
11. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
12. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165-2172.
13. Popat R, Oakervee HE, Curry N, et al. Reduced dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma [abstract]. Blood. 2005;106:717a. Abstract 2554.
14. Wang M, Delasalle K, Giralt S, et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy [abstract]. Blood. 2005;106:231a. Abstract 784.
15. Harousseau JL, Marit G, Caillot D, et al. VELCADE/dexamethasone (Val/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an interim analysis of the IFM 2005-01 randomized multicenter phase III trial [abstract]. Blood. 2006;108:21a. Abstract 56.
16. Popat R, Oakervee H, Curry N, et al. Long-term follow-up of PAD for untreated multiple myeloma [abstract]. Haematologica. 2007;92:725.
17. Kaufman JL, Gleason C, Heffner LT, et al. Bortezomib, thalidomide and dexamethasone as induction [abstract]. Haematologica. 2007;92:722.
18. Suvannasankha A, Smith GG, Juliar BE, Abonour R. Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma. 2006;7:131-134.
19. DeVos S, Dakhil SR, McLaughlin P, et al. Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular or marginal zone lymphoma: final results [abstract]. Blood. 2006;108(suppl):208a. Abstract 694.
20. O'Connor O, Hamlin P, Moskowitz C, et al. Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma [abstract]. J Clin Oncol. 2007;25(suppl):453s. Abstract 8051.
21. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mande cell lymphoma. J Clin Oncol. 2005;23:676-684.